Is eloralintide a GLP-1?

No. Eloralintide (LY3841136) is an amylin receptor agonist, not a GLP-1 drug. It mimics amylin, a hormone the pancreas releases with insulin after a meal, while GLP-1 drugs such as semaglutide mimic a gut hormone and act on a different receptor, the GLP-1 receptor. In cell assays, eloralintide favored the AMY1 amylin receptor by about 12-fold over the calcitonin receptor.

The two pathways act on separate brain circuits for fullness, which is why Lilly is testing eloralintide alongside tirzepatide rather than in place of it. Eloralintide is investigational, now in phase 3, and not FDA approved. Our eloralintide explainer covers the receptor pharmacology in depth. Each research vial is lot-tested, with reports in our COA library. Shop eloralintide for amylin research.

ELORALINTIDE 10MG
ELORALINTIDE 10MG